Great Point Partners as of June 30, 2021
Portfolio Holdings for Great Point Partners
Great Point Partners holds 30 positions in its portfolio as reported in the June 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Macrogenics (MGNX) | 7.8 | $37M | 1.4M | 26.86 | |
| Rocket Pharmaceuticals (RCKT) | 7.6 | $36M | 817k | 44.29 | |
| Arena Pharmaceuticals Com New | 7.2 | $35M | 506k | 68.20 | |
| United Therapeutics Corporation (UTHR) | 6.6 | $32M | 176k | 179.41 | |
| Insulet Corporation (PODD) | 6.0 | $29M | 105k | 274.51 | |
| Exelixis (EXEL) | 5.3 | $25M | 1.4M | 18.22 | |
| Collegium Pharmaceutical Inc Common Stock Usd (COLL) | 4.3 | $20M | 861k | 23.64 | |
| Kadmon Hldgs | 3.9 | $19M | 4.8M | 3.87 | |
| Intellia Therapeutics Call Option (NTLA) | 3.4 | $16M | 100k | 161.91 | |
| Mirati Therapeutics | 3.4 | $16M | 100k | 161.53 | |
| Travere Therapeutics (TVTX) | 3.3 | $16M | 1.1M | 14.59 | |
| Amicus Therapeutics (FOLD) | 3.2 | $15M | 1.6M | 9.64 | |
| Sage Therapeutics (SAGE) | 3.0 | $14M | 250k | 56.81 | |
| Dyne Therapeutics (DYN) | 3.0 | $14M | 673k | 21.04 | |
| Repare Therapeutics Ord (RPTX) | 2.9 | $14M | 436k | 31.18 | |
| Fibrogen Call Option (FGEN) | 2.8 | $13M | 500k | 26.63 | |
| Ocular Therapeutix (OCUL) | 2.7 | $13M | 920k | 14.18 | |
| Intersect Ent | 2.5 | $12M | 700k | 17.09 | |
| Puma Biotechnology (PBYI) | 2.5 | $12M | 1.3M | 9.18 | |
| Biogen Idec (BIIB) | 2.4 | $11M | 33k | 346.28 | |
| Magenta Therapeutics | 2.3 | $11M | 1.1M | 9.78 | |
| Kura Oncology (KURA) | 2.2 | $10M | 500k | 20.85 | |
| Anaptysbio Inc Common (ANAB) | 2.2 | $10M | 400k | 25.93 | |
| Olema Pharmaceuticals (OLMA) | 1.9 | $9.2M | 329k | 27.98 | |
| Tricida | 1.8 | $8.5M | 2.0M | 4.32 | |
| Inflarx Nv (IFRX) | 1.4 | $6.5M | 2.2M | 2.97 | |
| Rigel Pharmaceuticals Com New (RIGL) | 1.4 | $6.5M | 1.5M | 4.34 | |
| Cytomx Therapeutics (CTMX) | 1.3 | $6.3M | 1.0M | 6.33 | |
| Aeglea Biotherapeutics | 1.3 | $6.3M | 900k | 6.96 | |
| Verve Therapeutics (VERV) | 0.4 | $2.1M | 35k | 60.26 |
